𝔖 Bobbio Scriptorium

✦ LIBER ✦

472: Pre-transplant Busulfan Test Dose is a Reliable Alternative to First Busulfan IV Dose for Pharmacokinetics Studies in Allogeneic Hematopoietic Stem Cell Transplantation

✍ Scribed by R. Beri; S. Chunduri; C. Mactal-Haaf; K. Sweiss; L. Dobogai; B. Hurter; S. Shord; D. Peace; D. Rondelli

Book ID: 116280298
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 52 KB
Volume: 14
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2007.12.482

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Population pharmacokinetic study of a te

Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation

✍ Yasushi Takamatsu; Noriaki Sasaki; Kentaro Ogata; Eiji Yukawa; Shiro Jimi; Shuuj 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 253 KB

Twice-Daily Intravenous (IV) Busulfan (B

Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population

✍ I. Waxman; M.C. Milone; M. Bhatia; L. Shaw; V. Moore; B. Tallamy; O. Militano; J 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Pharmacokinetics of a Test Dose of Intra

Pharmacokinetics of a Test Dose of Intravenous Busulfan Guide Dose Modifications to Achieve an Optimal Area Under the Curve of a Single Daily Dose of Intravenous Busulfan in Children Undergoing a Reduced-Intensity Conditioning Regimen with Hematopoietic Stem Cell Transplantation

✍ Morris Kletzel; David Jacobsohn; Reggie Duerst 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Pharmacokinetic-Directed Dose Adjustment

Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America

✍ Lill, Michael; Costa, Luciano J.; Yeh, Rosa F.; Lim, Stephen; Stuart, Robert; Wa 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Identification of an AUC of 7603 Umol∗Mi

Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

✍ W.A. Wood; C.M. Walko; K.V. Rao; J. Whitley; D.T. Moore; D.A. Gabriel; J.S. Sero 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB

229: Twice-Daily Intravenous (IV) Busulf

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

✍ I. Waxman; M. Bhatia; M. Milone; L.M. Shaw; L. Baldinger; O. Militano; J. Garvin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB